Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IM156 with Gemcitabine and Nab-paclitaxel in Advanced Pancreatic Cancer
NCT05497778Phase 1Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2022
- Primary completion
- Feb 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lixumistat in pancreatic cancer (PC), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Adverse Events at 1 year. Started Oct 2022; status: active, not recruiting.
02
Drugs
lixumistat
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT05497778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05497778.